CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis

Zilong Yan, Kenoki Ouchida, Biao Zheng, Takashi Okumura, Shin Takesue, Hiromichi Nakayama, Chika Iwamoto, Koji Shindo, Taiki Moriyama, Kohei Nakata, Yoshihiro Miyasaka, Ohtsuka Takao, Kazuhiro Mizumoto, Yoshinao Oda, Makoto Hashizume, Masafumi Nakamura

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Purpose: This study aimed at investigating the function and significance of CD110 expression in pancreatic cancer. Methods: We performed immunohistochemical staining for CD110 expression in tumor samples from 86 patients with pancreatic cancer. We evaluated clinical outcomes and other clinicopathological factors to determine the significance of CD110 on survival and liver metastasis. We examine thrombopoietin–CD110 signaling in cancer cell extravasation in vitro and in vivo. We investigated the effects of CD110 knockdown on liver metastasis in a splenic xenograft mouse model. Results: CD110 expression in cancer cells was associated with low-histological-grade invasive ductal carcinoma, and patients with high CD110 expression had poorer prognosis (P = 0.0003). High CD110 expression was an independent predictor of liver metastasis (P = 0.0422). Knockdown of CD110 expression significantly attenuated cell migration and invasion. Treatment with thrombopoietin promoted pancreatic cancer cell extravasation. In the presence of thrombopoietin, CD110 increased cell viability through the activation of the ERK–MYC signaling pathway. Knockdown of CD110 expression inhibited liver metastases in the mouse model. Conclusions: CD110 promotes pancreatic cancer progression and it may serve as a predictive factor for liver metastasis.

元の言語英語
ページ(範囲)1147-1164
ページ数18
ジャーナルJournal of Cancer Research and Clinical Oncology
145
発行部数5
DOI
出版物ステータス出版済み - 5 1 2019

Fingerprint

Pancreatic Neoplasms
Neoplasm Metastasis
Liver
Thrombopoietin
Neoplasms
Ductal Carcinoma
Heterografts
Cell Movement
Cell Survival
Staining and Labeling
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. / Yan, Zilong; Ouchida, Kenoki; Zheng, Biao; Okumura, Takashi; Takesue, Shin; Nakayama, Hiromichi; Iwamoto, Chika; Shindo, Koji; Moriyama, Taiki; Nakata, Kohei; Miyasaka, Yoshihiro; Takao, Ohtsuka; Mizumoto, Kazuhiro; Oda, Yoshinao; Hashizume, Makoto; Nakamura, Masafumi.

:: Journal of Cancer Research and Clinical Oncology, 巻 145, 番号 5, 01.05.2019, p. 1147-1164.

研究成果: ジャーナルへの寄稿記事

Yan, Zilong ; Ouchida, Kenoki ; Zheng, Biao ; Okumura, Takashi ; Takesue, Shin ; Nakayama, Hiromichi ; Iwamoto, Chika ; Shindo, Koji ; Moriyama, Taiki ; Nakata, Kohei ; Miyasaka, Yoshihiro ; Takao, Ohtsuka ; Mizumoto, Kazuhiro ; Oda, Yoshinao ; Hashizume, Makoto ; Nakamura, Masafumi. / CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. :: Journal of Cancer Research and Clinical Oncology. 2019 ; 巻 145, 番号 5. pp. 1147-1164.
@article{edf8fb46abdd40aeb72e5ee962887748,
title = "CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis",
abstract = "Purpose: This study aimed at investigating the function and significance of CD110 expression in pancreatic cancer. Methods: We performed immunohistochemical staining for CD110 expression in tumor samples from 86 patients with pancreatic cancer. We evaluated clinical outcomes and other clinicopathological factors to determine the significance of CD110 on survival and liver metastasis. We examine thrombopoietin–CD110 signaling in cancer cell extravasation in vitro and in vivo. We investigated the effects of CD110 knockdown on liver metastasis in a splenic xenograft mouse model. Results: CD110 expression in cancer cells was associated with low-histological-grade invasive ductal carcinoma, and patients with high CD110 expression had poorer prognosis (P = 0.0003). High CD110 expression was an independent predictor of liver metastasis (P = 0.0422). Knockdown of CD110 expression significantly attenuated cell migration and invasion. Treatment with thrombopoietin promoted pancreatic cancer cell extravasation. In the presence of thrombopoietin, CD110 increased cell viability through the activation of the ERK–MYC signaling pathway. Knockdown of CD110 expression inhibited liver metastases in the mouse model. Conclusions: CD110 promotes pancreatic cancer progression and it may serve as a predictive factor for liver metastasis.",
author = "Zilong Yan and Kenoki Ouchida and Biao Zheng and Takashi Okumura and Shin Takesue and Hiromichi Nakayama and Chika Iwamoto and Koji Shindo and Taiki Moriyama and Kohei Nakata and Yoshihiro Miyasaka and Ohtsuka Takao and Kazuhiro Mizumoto and Yoshinao Oda and Makoto Hashizume and Masafumi Nakamura",
year = "2019",
month = "5",
day = "1",
doi = "10.1007/s00432-019-02860-z",
language = "English",
volume = "145",
pages = "1147--1164",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis

AU - Yan, Zilong

AU - Ouchida, Kenoki

AU - Zheng, Biao

AU - Okumura, Takashi

AU - Takesue, Shin

AU - Nakayama, Hiromichi

AU - Iwamoto, Chika

AU - Shindo, Koji

AU - Moriyama, Taiki

AU - Nakata, Kohei

AU - Miyasaka, Yoshihiro

AU - Takao, Ohtsuka

AU - Mizumoto, Kazuhiro

AU - Oda, Yoshinao

AU - Hashizume, Makoto

AU - Nakamura, Masafumi

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Purpose: This study aimed at investigating the function and significance of CD110 expression in pancreatic cancer. Methods: We performed immunohistochemical staining for CD110 expression in tumor samples from 86 patients with pancreatic cancer. We evaluated clinical outcomes and other clinicopathological factors to determine the significance of CD110 on survival and liver metastasis. We examine thrombopoietin–CD110 signaling in cancer cell extravasation in vitro and in vivo. We investigated the effects of CD110 knockdown on liver metastasis in a splenic xenograft mouse model. Results: CD110 expression in cancer cells was associated with low-histological-grade invasive ductal carcinoma, and patients with high CD110 expression had poorer prognosis (P = 0.0003). High CD110 expression was an independent predictor of liver metastasis (P = 0.0422). Knockdown of CD110 expression significantly attenuated cell migration and invasion. Treatment with thrombopoietin promoted pancreatic cancer cell extravasation. In the presence of thrombopoietin, CD110 increased cell viability through the activation of the ERK–MYC signaling pathway. Knockdown of CD110 expression inhibited liver metastases in the mouse model. Conclusions: CD110 promotes pancreatic cancer progression and it may serve as a predictive factor for liver metastasis.

AB - Purpose: This study aimed at investigating the function and significance of CD110 expression in pancreatic cancer. Methods: We performed immunohistochemical staining for CD110 expression in tumor samples from 86 patients with pancreatic cancer. We evaluated clinical outcomes and other clinicopathological factors to determine the significance of CD110 on survival and liver metastasis. We examine thrombopoietin–CD110 signaling in cancer cell extravasation in vitro and in vivo. We investigated the effects of CD110 knockdown on liver metastasis in a splenic xenograft mouse model. Results: CD110 expression in cancer cells was associated with low-histological-grade invasive ductal carcinoma, and patients with high CD110 expression had poorer prognosis (P = 0.0003). High CD110 expression was an independent predictor of liver metastasis (P = 0.0422). Knockdown of CD110 expression significantly attenuated cell migration and invasion. Treatment with thrombopoietin promoted pancreatic cancer cell extravasation. In the presence of thrombopoietin, CD110 increased cell viability through the activation of the ERK–MYC signaling pathway. Knockdown of CD110 expression inhibited liver metastases in the mouse model. Conclusions: CD110 promotes pancreatic cancer progression and it may serve as a predictive factor for liver metastasis.

UR - http://www.scopus.com/inward/record.url?scp=85061613526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061613526&partnerID=8YFLogxK

U2 - 10.1007/s00432-019-02860-z

DO - 10.1007/s00432-019-02860-z

M3 - Article

C2 - 30770989

AN - SCOPUS:85061613526

VL - 145

SP - 1147

EP - 1164

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 5

ER -